Avadel PharmaceuticalsAVDL
13F holders, Q1 2026 (March 31)1holders −205
0new positions
201sold out
$21.30avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Avadel Pharmaceuticals Ltd. (AVDL) in their 13F filings, down 205 from Q4 2025. 0 opened new positions and 201 sold out. The largest holder was IFP Advisors, Inc ($426).
- Company
- Avadel Pharmaceuticals Ltd.
- CUSIP
- G29687103
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 201 | $1.4B |
All 13F filers, Q4 2025 → Q1 2026: 66,916,886 shares sold, net −66,916,886 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| IFP Advisors, Inc | 0.00% | No change | 20 | $426 |
"% of holder's portfolio" is AVDL's weight in each manager's 13F, not the share of Avadel Pharmaceuticals Ltd. the manager owns.